Allspring Global Investments Holdings LLC Has $1.08 Million Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Allspring Global Investments Holdings LLC increased its stake in MiMedx Group, Inc. (NASDAQ:MDXG) by 1.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 183,021 shares of the company’s stock after acquiring an additional 1,822 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.12% of MiMedx Group worth $1,082,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY increased its holdings in MiMedx Group by 6.6% during the second quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company’s stock worth $28,879,000 after buying an additional 258,700 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in MiMedx Group by 47.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock worth $8,958,000 after buying an additional 413,443 shares in the last quarter. Millennium Management LLC increased its stake in MiMedx Group by 339.9% in the second quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock valued at $6,164,000 after acquiring an additional 687,267 shares during the last quarter. Russell Investments Group Ltd. raised its position in MiMedx Group by 5.0% during the first quarter. Russell Investments Group Ltd. now owns 551,546 shares of the company’s stock valued at $4,247,000 after purchasing an additional 26,487 shares in the last quarter. Finally, Hillsdale Investment Management Inc. lifted its stake in MiMedx Group by 8.6% during the first quarter. Hillsdale Investment Management Inc. now owns 486,500 shares of the company’s stock worth $3,746,000 after purchasing an additional 38,600 shares during the last quarter. Institutional investors own 79.15% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on MDXG. StockNews.com raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Craig Hallum dropped their target price on MiMedx Group from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $11.00 price target on shares of MiMedx Group in a research note on Thursday, August 1st. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.00.

MiMedx Group Trading Up 20.4 %

MDXG opened at $6.85 on Friday. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $9.27. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.85 and a quick ratio of 3.22. The business has a 50 day simple moving average of $6.06 and a two-hundred day simple moving average of $6.66. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of 12.23 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.08 EPS for the quarter, hitting the consensus estimate of $0.08. MiMedx Group had a net margin of 23.63% and a return on equity of 34.24%. The business had revenue of $87.21 million for the quarter, compared to analyst estimates of $88.44 million. Analysts predict that MiMedx Group, Inc. will post 0.26 EPS for the current year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.